» Articles » PMID: 34596369

Continuous Glucose Monitoring Systems in Well-controlled Children with Type 1 Diabetes Mellitus

Overview
Publisher Termedia
Specialty Pediatrics
Date 2021 Oct 1
PMID 34596369
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Numerous studies have demonstrated the clinical benefits of using continuous glucose monitoring (CGM) systems among patients with type 1 diabetes (T1D). Aim of the study was to assess the effectiveness of CGM on metabolic control in children with T1D and well-controlled disease prior to the study.

Material And Methods: This prospective analysis included 99 children (46 girls) at the median age of 11.23 years and diabetes duration of at least 1 year (median: 5.16 years), generally well controlled metabolically (median HbA1c: 7.0%), and treated with continuous subcutaneous insulin infusion (CSII). The patients had used CGM for at least 150 days. We analysed the participants in subgroups based on baseline HbA1c < 7%, ≥ 7%, age, and sex.

Results: Children with baseline HbA1c < 7% were characterized by significantly increased HbA1c after the median of 273 days (217; 320) of CGM usage (6.3% vs. 6.6%, respectively; p = 0.002). No significant change in HbA1c was noted in children with baseline HbA1c ≥ 7% (7.5% vs. 7.4%, respectively; p = 0.191), but 20% of the group reached the target of HbA1c < 7.0%. The analysis of CGM data revealed that no group achieved the CGM targets of good metabolic control. Total daily insulin requirements remained stable in both groups (p = 0.752; p = 0.274), but the amount of basal insulin increased statistically in both groups (p = 0.009; p ≤ 0.001).

Conclusions: The application of CGM provides detailed information concerning glycaemic control and is beneficial in some, but not all, T1D children with good diabetes control.

Citing Articles

Weight gain in type 1 diabetes during the SARS-CoV-2 pandemic. Does lockdown affect the metabolic control of pediatric patients?.

Zubkiewicz-Kucharska A, Wikiera B, Noczynska A Front Endocrinol (Lausanne). 2022; 13:991269.

PMID: 36313778 PMC: 9597863. DOI: 10.3389/fendo.2022.991269.


Effect of nationwide reimbursement of real-time continuous glucose monitoring on HbA1c, hypoglycemia and quality of life in a pediatric type 1 diabetes population: The RESCUE-pediatrics study.

De Ridder F, Charleer S, Jacobs S, Bolsens N, Ledeganck K, Van Aken S Front Pediatr. 2022; 10:991633.

PMID: 36275049 PMC: 9582657. DOI: 10.3389/fped.2022.991633.


Paediatric diabetes care 100 years after insulin discovery - closer to closing the loop but still yearning for the cure.

Mianowska B Pediatr Endocrinol Diabetes Metab. 2021; 27(3):149-150.

PMID: 34743500 PMC: 10228198. DOI: 10.5114/pedm.2021.109489.

References
1.
Joubert M, Reznik Y . Personal continuous glucose monitoring (CGM) in diabetes management: review of the literature and implementation for practical use. Diabetes Res Clin Pract. 2012; 96(3):294-305. DOI: 10.1016/j.diabres.2011.12.010. View

2.
Rodbard D . Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. Diabetes Technol Ther. 2017; 19(S3):S25-S37. PMC: 5467105. DOI: 10.1089/dia.2017.0035. View

3.
De Block C, Manuel-y-Keenoy B, Van Gaal L . A review of current evidence with continuous glucose monitoring in patients with diabetes. J Diabetes Sci Technol. 2009; 2(4):718-27. PMC: 2769750. DOI: 10.1177/193229680800200426. View

4.
Chetty V, Almulla A, Odueyungbo A, Thabane L . The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in Type I diabetic patients: a systematic review. Diabetes Res Clin Pract. 2008; 81(1):79-87. DOI: 10.1016/j.diabres.2008.02.014. View

5.
Tamborlane W, Beck R, Bode B, Buckingham B, Peter Chase H, Clemons R . Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359(14):1464-76. DOI: 10.1056/NEJMoa0805017. View